These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 24969733)

  • 1. Impact of body mass index on suppression of follicular development and ovulation using a transdermal patch containing 0.55-mg ethinyl estradiol/2.1-mg gestodene: a multicenter, open-label, uncontrolled study over three treatment cycles.
    Westhoff CL; Reinecke I; Bangerter K; Merz M
    Contraception; 2014 Sep; 90(3):272-9. PubMed ID: 24969733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A two-centre, open-label, randomised study of ovulation inhibition with three transdermal contraceptive patches, each containing different amounts of ethinyl estradiol and gestodene in healthy, young women.
    Waellnitz K; Duijkers I; Klipping C; Rautenberg T; Rohde B; Zurth C
    J Obstet Gynaecol; 2016; 36(1):106-13. PubMed ID: 26421957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of bleeding patterns and cycle control using two transdermal contraceptive systems: a multicenter, open-label, randomized study.
    Gruber D; Skřivánek A; Serrani M; Lanius V; Merz M
    Contraception; 2015 Feb; 91(2):105-12. PubMed ID: 25453582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian activity during regular oral contraceptive use.
    Crosignani PG; Testa G; Vegetti W; Parazzini F
    Contraception; 1996 Nov; 54(5):271-3. PubMed ID: 8934059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications of different application sites on the bioavailability of a transdermal contraceptive patch containing ethinyl estradiol and gestodene: an open-label, randomized, crossover study.
    Höchel J; Schuett B; Ludwig M; Zurth C
    Int J Clin Pharmacol Ther; 2014 Oct; 52(10):856-66. PubMed ID: 25138681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bleeding pattern and cycle control of a low-dose transdermal contraceptive patch compared with a combined oral contraceptive: a randomized study.
    Merz M; Kroll R; Lynen R; Bangerter K
    Contraception; 2015 Feb; 91(2):113-20. PubMed ID: 25453585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open-label, two-period comparative study on pharmacokinetics and safety of a combined ethinylestradiol/gestodene transdermal contraceptive patch.
    Zhang C; Li H; Xiong X; Zhai S; Wei Y; Zhang S; Zhang Y; Xu L; Liu L
    Drug Des Devel Ther; 2017; 11():725-731. PubMed ID: 28331292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovarian activity and safety of a novel levonorgestrel/ethinyl estradiol continuous oral contraceptive regimen.
    Archer DF; Kovalevsky G; Ballagh SA; Grubb GS
    Contraception; 2009 Sep; 80(3):245-53. PubMed ID: 19698816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative study of two contraceptive vaginal rings releasing norethindrone acetate and differing doses of ethinyl estradiol.
    Weisberg E; Fraser IS; Mishell DR; Lacarra M; Darney P; Jackanicz TM
    Contraception; 1999 May; 59(5):305-10. PubMed ID: 10494484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovulatory effects of three oral contraceptive regimens: a randomized, open-label, descriptive trial.
    Seidman L; Kroll R; Howard B; Ricciotti N; Hsieh J; Weiss H
    Contraception; 2015 Jun; 91(6):495-502. PubMed ID: 25746294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovarian activity in obese and nonobese women treated with three transdermal contraceptive patches delivering three different doses of ethinyl estradiol and levonorgestrel.
    Foegh M; Archer DF; Stanczyk FZ; Rubin A; Mishell DR
    Contraception; 2013 Feb; 87(2):201-11. PubMed ID: 23036478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined ethinylestradiol/gestodene contraceptive patch: two-center, open-label study of ovulation inhibition, acceptability and safety over two cycles in female volunteers.
    Heger-Mahn D; Warlimont C; Faustmann T; Gerlinger C; Klipping C
    Eur J Contracept Reprod Health Care; 2004 Sep; 9(3):173-81. PubMed ID: 15697107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Follicular development in a 7-day versus 4-day hormone-free interval with an oral contraceptive containing 20 mcg ethinyl estradiol and 1 mg norethindrone acetate.
    Rible RD; Taylor D; Wilson ML; Stanczyk FZ; Mishell DR
    Contraception; 2009 Mar; 79(3):182-8. PubMed ID: 19185670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic overview of ethinyl estradiol dose and bioavailability using two transdermal contraceptive systems and a standard combined oral contraceptive.
    Hofmann B; Reinecke I; Schuett B; Merz M; Zurth C
    Int J Clin Pharmacol Ther; 2014 Dec; 52(12):1059-70. PubMed ID: 25295716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women.
    Westhoff CL; Torgal AH; Mayeda ER; Pike MC; Stanczyk FZ
    Contraception; 2010 Jun; 81(6):474-80. PubMed ID: 20472113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a low-dose contraceptive patch on efficacy, bleeding pattern, and safety: a 1-year, multicenter, open-label, uncontrolled study.
    Wiegratz I; Bassol S; Weisberg E; Mellinger U; Merz M
    Reprod Sci; 2014 Dec; 21(12):1518-25. PubMed ID: 24784719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 1, multicentre, open-label study to evaluate ovarian follicular activity and hormone levels with an extended-regimen combined oral contraceptive with low-dose ethinyl estradiol supplementation.
    Kroll R; Seidman L; Ricciotti N; Howard B; Weiss H
    Eur J Contracept Reprod Health Care; 2015; 20(4):249-58. PubMed ID: 25522805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity.
    Sullivan H; Furniss H; Spona J; Elstein M
    Fertil Steril; 1999 Jul; 72(1):115-20. PubMed ID: 10428158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized study of the effect of mifepristone alone or in conjunction with ethinyl estradiol on ovarian function in women using the etonogestrel-releasing subdermal implant, Implanon®.
    Weisberg E; Croxatto HB; Findlay JK; Burger HG; Fraser IS
    Contraception; 2011 Dec; 84(6):600-8. PubMed ID: 22078189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and adhesion of a transdermal patch containing ethinyl estradiol and gestodene under conditions of heat, humidity, and exercise: A single-center, open-label, randomized, crossover study.
    Zurth C; Schuett B; Casjens M; Ludwig M; Waellnitz K
    Clin Pharmacol Drug Dev; 2015 Jul; 4(4):245-55. PubMed ID: 27136904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.